<DOC>
	<DOCNO>NCT02587078</DOCNO>
	<brief_summary>The primary alternative hypothesis less time ( minute ) require , achieve initial hemodynamic stabilization , Volulyte® compare Jonosteril® . - H01 : Minutes Volulyte® ≥ Minutes Jonosteril® - H11 : Minutes Volulyte® &lt; Minutes Jonosteril®</brief_summary>
	<brief_title>Volume Therapy With Crystalloids Colloids Hemodynamic Monitoring Patients With Severe Sepsis</brief_title>
	<detailed_description>Comparative , multicenter , active-controlled , parallel-group , double-blind , randomize study . Patients meet inclusion criterion ( Screening , see definition ) randomize immediately ratio 1:1 either receive intravenous Volulyte® Jonosteril® fluid resuscitation ( RAND ) . Fluid resuscitation study drug start immediately order reach initial hemodynamic stabilization . Assessment effect fluid resuscitation achieve primary secondary endpoint perform 24 hour follow randomization . Initial hemodynamic stabilization define normalization mean arterial pressure ( MAP ) , central venous oxygen saturation ( ScvO2 ) PPV ( pulse pressure variation ) response PLR ( passive leg rise ) define maintain normalization period 1 hour , increase infusion vasopressor , inotropic therapy ≤ 250ml additional study drug administration within 1 hour . The normalization parameter MAP PPV ( pulse pressure variation ) PLR ( passive leg rise ) ScvO2 define follow : - MAP : ≥ 65 mmHg - ScvO2 : ≥ 70 % - PPV : ≤ 12 % ( premise : sinus rhythm , spontaneous breathe effort mechanical ventilation VT : 5 - &lt; 6 ml/kg ) . If PPV applicable , response PLR-manoeuvre use ( see ) . ● PLR : &lt; 10 % change cardiac output ( CO )</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>1 . Prior write informed consent patient . If possible , necessary investigator obtain initial informed consent accord requirement . The legally authorize representative provide write informed consent absence declaration inclusion emergency situation sign consultant physician involve study independent investigational team . If patient dy follow inclusion clinical trial base consult physician´s vote legally authorize representative available / able give inform consent , additional inform consent need consultant physician´s vote consider sufficient . 2 . Male female patient age 18 year old 3 . Presence severe sepsis define : Sepsis due know suspected infection two modify systemic inflammatory response syndrome ( SIRS ) criterion ( 46 ) . Temperature ( &gt; 38°C &lt; 36°C ) Heart rate ( &gt; 90 beat / minute ) Respiratory rate ( &gt; 20 breath / minute ) arterial carbon dioxide ( PaCO2 ) &lt; 32 mmHg ( &lt; 4.3 kPa ) White blood cell ( WBC ) &gt; 12.000 cells/mm3 , &lt; 4000 cells/mm3 , &gt; 10 % immature ( band ) form Severe sepsis le 24 hour least one follow characteristic : Ratio partial pressure oxygen fraction inspire oxygen ( PaO2/FiO2 ) &lt; 250 Arterial pH &lt; 7.3 serum lactate level &gt; 1.5 × ULN ( upper limit normal ) Hypotension : Inadequately fluid resuscitate patient systolic blood pressure ≤ 90 mmHg MAP ≤ 70 mmHg , adequately fluid resuscitate patient require vasopressor maintain blood pressure within normal range Urine output &lt; 0.5 ml/kg/hour ( patient inadequately fluid resuscitate ) Platelet count &lt; 80.000/ mm3 Acute alteration mental status 4 . Requirement fluid resuscitation define measure hemodynamic parameter MAP , ScvO2 PPV PLR . 1 . Volume expansion dosage HES administer prior randomization render patient unsuitable inclusion base treat physician´s discretion consideration suggest maximal dose/day . 2 . Known volume expansion dosage HES 200.000 prior inclusion actual hospital admission . 3 . Participation another clinical study investigational drug investigational medical device within 30 day screen planned study period . 4 . Known hypersensitivity component investigated solution . 5 . Known pregnancy ; female patient must surgically sterile ; postmenopausal least two year ; childbearing potential must negative serum urine dipstick pregnancy test ( test result available time randomization , patient may randomize treat initially , however , withdraw immediately study soon test result becomes available positive ) . 6 . Known serum creatinine &gt; 300 μmol/L , correspond 3.4 mg/dL ( serum creatinine value available time randomization available value old 24 hour , patient may randomize treat . If creatinine value &gt; 300 μmol/L becomes available later , treatment study drug may continue risk/benefit ratio individual patient regard positive investigator . ) 7 . Known history chronic renal failure ( hemodialysis ) 8 . Anuria last 8 hour ( &lt; 50ml urine output / 8 hour ) despite fluid resuscitation prior randomization . 9 . Requirement renal support ( either continuous discontinuous technique , include intermittent hemodialysis , hemofiltration hemodiafiltration ) 10 . History know hemostatic disorder clinical bleeding ( hemophilia know suspected Willebrand disease ) 11 . Burns &gt; 20 % body surface 12 . State brain death 13 . Known comorbidities : Hematologic malignant disorder , neutropenia ( polymorphonuclear leukocytes [ PMN ] &lt; 500/mm3 ) , proven liver cirrhosis , Aquired immunodeficiency syndrome ( AIDS ) Expected requirement concomitant cancer therapy ( e.g . chemotherapradiotherapy surgery ) randomization Day 4 Requirement concomitant cancer therapy ( e.g . chemotherapy , radiotherapy surgery ) randomization Day 4 14 . Known fluid overload ( EVLWI &gt; 10 ml/kg BW ) 15 . Need fluid restriction 16 . Refractory septic shock define severe sepsis hypotension unresponsive adequate fluid resuscitation , along presence hypoperfusion abnormality organ dysfunction define Bone et al. , 1992 . Patients receive inotropic vasopressor agent may longer hypotensive time manifest hypoperfusion abnormality organ dysfunction , yet would still consider septic shock . Patients treat low dose vasopressor exclude provided responsive fluid resuscitation demonstrate individual fluid challenge . Patients receive norepinephrine ( noradrenaline ) epinephrine ( adrenaline ) dose &gt; 0.5 μg/kg/min dopamine dose &gt; 15 μg/kg/min timepoint Screening eligible study . 17 . Intracranial bleed 18 . Any condition render patient unsuitable inclusion base treat physician´s discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Haemodynamic stabilization</keyword>
</DOC>